CoChat

Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells

Open access
Li, Hongyu, Hu, Jing, Wu, Shuhong, Wang, Li, Cao, Xiaobo, Zhang, Xiaoshan, Dai, Bingbing, Cao, Mengru, Shao, Ruping, Zhang, Ran, Majidi, Mourad, Ji, Lin, Heymach, John V., Wang, Michael, Pan, Shiyang, Minna, John, Mehran, Reza J., Swisher, Stephen G., Roth, Jack A., Fang, Bingliang · 2016 · Oncotarget
Cited by 147

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

// Hongyu Li 1, 4 , Jing Hu 1 , Shuhong Wu 1 , Li Wang 1 , Xiaobo Cao 1 , Xiaoshan Zhang 1 , Bingbing Dai 1 , Mengru Cao 1 , Ruping Shao 1 , Ran Zhang 1 , Mourad Majidi 1 , Lin Ji 1 , John V. Heymach 2 , Michael Wang 3 , Shiyang Pan 5 , John Minna 6 , Reza J. Mehran 1 , Stephen G. Swisher 1 , Jack A. Roth 1 , and Bingliang Fang 1 1 Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2 Department of Thoracic/Head & Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3 Department of Lymphoma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA 4 Jilin Province Cancer Hospital, Changchun, Jilin, China 5 Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China 6 Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA Correspondence to: Bingliang Fang, e-mail: bfang@mdanderson.org Keywords: lung cancer, drug repurposing, anticancer agent, biomarkers Received: August 19, 2015 Accepted: November 21, 2015 Published: December 09, 2015 ABSTRACT Auranofin, a gold complex that has been used to treat rheumatoid arthritis in clinics and has documented pharmacokinetic and safety profiles in humans, has recently been investigated for its anticancer activity in leukemia and some solid cancers. However, auranofin’s single agent activity in lung cancer is not well characterized. To determine whether auranofin has single agent activity in lung cancer, we evaluated auranofin’s activity in a panel of 10 non-small cell lung cancer (NSCLC) cell lines. Cell viability analysis revealed that auranofin induced growth inhibition in a subset of NSCLC cell lines with a half maximal inhibitory concentration (IC 50 ) below 1.0 μM. Treatment with auranofin elicited apoptosis and necroptosis in auranofin-sensitive cell lines. Moreover, the susceptibility of NSCLC cells to auranofin was inversely correlated with TXNRD1 expression in the cells. Transient transfection of the TXNRD1-expressing plasmid in auranofin-sensitive Calu3 cells resulted in partial resistance, indicating that high TXNRD level is one of causal factors for resistance to auranofin. Further mechanistic characterization with proteomic analysis revealed that auranofin inhibits expression and/or phosphorylation of multiple key nodes in the PI3K/AKT/mTOR pathway, including S6, 4EBP1, Rictor, p70S6K, mTOR, TSC2, AKT and GSK3. Ectopic expression of TXNRD1 partially reversed auranofin-mediated PI3K/AKT/mTOR inhibition, suggesting that TXNRD1 may participate in the regulation of PI3K/AKT/mTOR pathway. Administration of auranofin to mice with xenograft tumors derived from NSCLC cells significantly suppressed tumor growth without inducing obvious toxic effects. Our results demonstrated feasibility of repurposing auranofin for treatment of lung cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.6516

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 147

Metadata

Authors
Li, H., Hu, J., Wu, S., Wang, L., Cao, X., Zhang, X., Dai, B., Cao, M., Shao, R., Zhang, R., Majidi, M., Ji, L., Heymach, J. V., Wang, M., Pan, S., Minna, J., Mehran, R. J., Swisher, S. G., Roth, J. A., & Fang, B.
Venue
Oncotarget
Published
2015-12-09
Volume
7
Issue
3
Pages
3548-3558
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2193658266
Cited by
147
References
9
FWCI
4.37
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. https://app.cochat.ai/papers/10.18632/oncotarget.6516
The paper
Li, H., Hu, J., Wu, S., Wang, L., Cao, X., Zhang, X., Dai, B., Cao, M., Shao, R., Zhang, R., Majidi, M., Ji, L., Heymach, J. V., Wang, M., Pan, S., Minna, J., Mehran, R. J., Swisher, S. G., Roth, J. A., & Fang, B. (2016). Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget. https://doi.org/10.18632/oncotarget.6516

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.